Results 181 to 190 of about 6,466,330 (328)

Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.

Journal of the National Cancer Institute, 2014
A. Templeton, M. McNamara, B. Šeruga, F. Vera-Badillo, P. Aneja, A. Ocaña, R. Leibowitz-Amit, G. Sonpavde, J. Knox, B. Tran, I. Tannock, E. Amir   +11 more
semanticscholar   +1 more source

Impact of APOE ε4 Genotype Load on Cognitive Function and Lipid Metabolism in Patients With Cerebral Small Vessel Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Apolipoprotein ε4 (APOE ε4) is a potent genetic risk factor for Alzheimer's disease (AD). However, its role in cerebral small vessel disease (CSVD) remains unclear. Given the clinical and pathological similarities between CSVD and AD, this study aimed to investigate the associations of APOE ε4 gene dosage with cognitive function and
Tingru Jin, Haocheng Yang, Feng Liu, Sihao Lin, Junru Hu, Jian Wang, Yulan Gou   +6 more
wiley   +1 more source

Calculated hazards using survival discrete analysis expressed as percentages and odds ratios in the acute care center.

Jorge L. Martinez-Cajas (22049710), Beatriz Alvarado (4709251), Ann Jolly (524581), Yanping Gong (406465), Bradley Stoner (20987213), Gerald Evans (8449662), Santiago Perez-Patrigeon (252528), T. Hugh Guan (11858559)   +7 more
openalex   +1 more source

Hazard Ratio Bias in Cohort Studies

Epidemiology, 2013
Jia-Chun, Lin, Wen-Chung, Lee
openaire   +2 more sources

Amyotrophic Lateral Sclerosis Prevalence Projection in 2040: A Less Rare Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To project ALS prevalence across multiple countries through 2040, accounting for both population aging and increased survival. Methods Data from the Piemonte and Valle d'Aosta ALS register (PARALS) was used to estimate the trends in incidence and prevalence from 2005 to 2019. Survival trends over this period were also assessed.
Rosario Vasta, Stefano Callegaro, Antonio Canosa, Umberto Manera, Maurizio Grassano, Francesca Palumbo, Sara Cabras, Enrico Matteoni, Francesca Di Pede, Filippo De Mattei, Salvatore Tafaro, Neil M. Thakur, Ryan Grosenick, Fabiola De Marchi, Letizia Mazzini, Cristina Moglia, Andrea Calvo, Kuldip D. Dave, Adriano Chiò   +18 more
wiley   +1 more source

A Comparison of Additional Benefit Assessment Methods for Time-to-Event Endpoints Using Hazard Ratio Point Estimates or Confidence Interval Limits by Means of a Simulation Study. [PDF]

Med Decis Making
Büsch CA, Kirchner M, Behnisch R, Kieser M.   +3 more
europepmc   +1 more source

Marginal hazard ratio estimates in joint frailty models for heart failure trials. [PDF]

Biom J, 2019
Toenges G, Jahn-Eimermacher A.
europepmc   +1 more source

Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu, Oliver Robinson, Christina M. Lill, Anna Matton, Raquel Puerta, Pilar Sanz, Merce Boada, Agustín Ruiz, Lefkos Middleton, for the Alzheimer's Disease Neuroimaging Initiative   +9 more
wiley   +1 more source

Instrumental variable approach for estimating a causal hazard ratio: application to the effect of postmastectomy radiotherapy on breast cancer patients. [PDF]

Obs Stud, 2019
Yang F, Cheng J, Huo D.
europepmc   +1 more source

Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer. [PDF]

Transl Lung Cancer Res, 2020
Chen H, Horita N, Ito K, Hara Y, Kobayashi N, Kaneko T.   +5 more
europepmc   +1 more source